

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7944113

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
OXFORD FINANCE LLC	05/04/2023
RECEIVING PARTY DATA	
Name:	NOVAQUEST CO-INVESTMENT FUND X, L.P.
Street Address:	4208 SIX FORKS ROAD, SUITE 920
City:	RALEIGH
State/Country:	NORTH CAROLINA
Postal Code:	27609
PROPERTY NUMBERS Total: 54	
Property Type	Number
Patent Number:	10251875
Patent Number:	10568875
Patent Number:	10583132
Patent Number:	10610525
Patent Number:	10576074
Patent Number:	11071732
Patent Number:	11464769
Patent Number:	11273141
Patent Number:	10226436
Patent Number:	10159657
Patent Number:	10471026
Patent Number:	10420735
Patent Number:	10646458
Patent Number:	10568850
Patent Number:	11413259
Patent Number:	10052296
Patent Number:	10874626
Patent Number:	11547686
Patent Number:	10682308
Patent Number:	10722453

Property Type	Number
Patent Number:	10722454
Patent Number:	10722455
Patent Number:	10869845
Patent Number:	11491121
Patent Number:	10653646
Patent Number:	11071719
Patent Number:	11207280
Patent Number:	11083698
Application Number:	17861752
Application Number:	17872450
Application Number:	17098923
Application Number:	18076264
Application Number:	18011664
Application Number:	63314724
Application Number:	16909340
Application Number:	17960343
Application Number:	17526786
Application Number:	17007816
Application Number:	17007900
Application Number:	17016186
Application Number:	17145589
Application Number:	17685286
Application Number:	63414779
Application Number:	63419650
Application Number:	63419675
Application Number:	63348256
Application Number:	63402374
Application Number:	17591944
PCT Number:	US2220246
PCT Number:	IB2022054864
PCT Number:	US2143061
PCT Number:	US2022017997
PCT Number:	US2216636
PCT Number:	US2022031982

CORRESPONDENCE DATA

Fax Number: (919)781-4865

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 919.882.7143
Email: ip@wyrick.com
Correspondent Name: DEVON E. WHITE
Address Line 1: 4101 LAKE BOONE TRAIL, SUITE 300
Address Line 2: WYRICK ROBBINS YATES & PONTON LLP
Address Line 4: RALEIGH, NORTH CAROLINA 27607

ATTORNEY DOCKET NUMBER:	024658.0066
--------------------------------	-------------

NAME OF SUBMITTER:	DEVON E WHITE
---------------------------	---------------

SIGNATURE:	/dew/
-------------------	-------

DATE SIGNED:	05/09/2023
---------------------	------------

Total Attachments: 9

source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page1.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page2.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page3.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page4.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page5.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page6.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page7.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page8.tif
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page9.tif

ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “**Assignment**”), dated as of May 4, 2023, is by OXFORD FINANCE LLC, a Delaware limited liability company (“**Oxford Finance**”), acting in its capacity as the current and assigning collateral agent (in such capacity, the “**Assignor Agent**”), and NovaQuest Co-Investment Fund X, L.P., a Delaware limited partnership (“**NovaQuest**”), acting in its capacity as the assignee collateral agent (in such capacity, the “**Assignee Agent**”).

WHEREAS, Nevakar Inc., a Delaware corporation, Vyluma Inc., a Delaware corporation, and Nevakar Injectables Inc., a Delaware corporation, collectively, as “**Grantor**”, and Assignor Agent are parties to that certain Intellectual Property Security Agreement, dated as of January 10, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “**Agreement**”) covering certain intellectual property set forth on **Exhibits A, B, C, and D** attached hereto; and

WHEREAS, pursuant to that certain Assignment of Loans, Liens and Loan Documents by and among Oxford Finance, as the Assignor Agent and a lender, NovaQuest, and certain other parties thereto, dated as of the date hereof, Assignor Agent has assigned to Assignee Agent all of its rights, remedies, duties and other obligations under, among other documents, the Agreement, in each instance, in its capacity as collateral agent under the Agreement.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor Agent hereby assigns and transfers to Assignee Agent and its successors and assigns, all of its rights, title and interest in and to the Agreement.

This Assignment may be executed in any number of counterparts, each of which when so executed shall be deemed an original and all of which taken together shall constitute one and the same instrument.

(Remainder of page left intentionally blank; signatures follow.)

IN WITNESS WHEREOF, Assignor Agent and Assignee Agent have caused this Assignment to be duly executed as of the date first above written.

ASSIGNOR AGENT:

OXFORD FINANCE LLC

By: _____

Name: Colette H. Featherly

Title: Senior Vice President

ASSIGNEE AGENT:

NOVAQUEST CO-INVESTMENT FUND X, L.P.

By: NQ POF V GP, Ltd., its general partner

By: _____
John L. Bradley, Jr., Director

IN WITNESS WHEREOF, Assignor Agent and Assignee Agent have caused this Assignment to be duly executed as of the date first above written.

ASSIGNOR AGENT:

OXFORD FINANCE LLC

By: _____
Name: _____
Title: _____

ASSIGNEE AGENT:

NOVAQUEST CO-INVESTMENT FUND X, L.P.

By: NQ POF V GP, Ltd., its general partner

By: 
John L. Bradley, Jr., Director

EXHIBIT "A"

Copyrights

None.

EXHIBIT "B"

Patents

Owner	Description	Patent/App. No.	File Date	Jurisdiction
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10251875	10 May 2018	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10568875	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10583132	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10610525	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10576074	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 11071732	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 11464769	20 July 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17007816	31 August 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17007900	31 August 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17016186	9 September 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17145589	11 January 2021	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17685286	2 March 2022	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	3,063,228	10 May 2018	Canada
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6557379	10 May 2018	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6865476	10 May 2018	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6681502	11 July 2019	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6681503	11 July 2019	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	2021-56894	11 July 2019	Japan
Vyluma Inc.	Atropine Pharmaceutical Compositions	3548000	8 July 2019	Europe
Vyluma Inc.	Atropine Pharmaceutical Compositions	21205568.5	29 October 2021	Europe
Vyluma Inc.	Atropine Pharmaceutical Compositions	AU 2018265257	25 October 2019	Australia
Vyluma Inc.	Atropine Pharmaceutical Compositions	NZ 758555	25 October 2019	New Zealand
Vyluma Inc.	Atropine Pharmaceutical Compositions	BR 1120190235159	25 October 2019	Brazil
Vyluma Inc.	Atropine Pharmaceutical Compositions	392558	25 October 2019	Mexico
Vyluma Inc.	Atropine Pharmaceutical Compositions	11201910085U	25 October 2019	Singapore
Vyluma Inc.	Atropine Pharmaceutical Compositions	1-2019-06890	6 December 2019	Vietnam
Vyluma Inc.	Atropine Pharmaceutical Compositions	10-2281667	6 December 2019	Korea
Vyluma Inc.	Atropine Pharmaceutical Compositions	IDP000082353	29 November 2019	Indonesia
Vyluma Inc.	Atropine Pharmaceutical Compositions	40310	28 November 2019	Colombia
Vyluma Inc.	Atropine Pharmaceutical Compositions	201903228	11 November 2019	Chile
Vyluma Inc.	Atropine Pharmaceutical Compositions	2745603	11 December 2019	Russia
Vyluma Inc.	Atropine Pharmaceutical Compositions	2019/19945	11 December 2019	Turkey
Vyluma Inc.	Atropine Pharmaceutical Compositions	201927047383	20 November 2019	India
Vyluma Inc.	Atropine Pharmaceutical Compositions	1-2019-502701	28 November 2019	Philippines
Vyluma Inc.	Atropine Pharmaceutical Compositions	110621298 B	11 November 2019	China
Vyluma Inc.	Atropine Pharmaceutical Compositions	42022058129	9 April 2020	Hong Kong
Vyluma Inc.	Multi-dose Container for Ophthalmic Compositions	PCT/US22/20246	14 March 2022	PCT Countries
Vyluma Inc.	Childhood Atropine for Myopia Progression	US 63414779	10 October 2022	USA
Vyluma Inc.	Childhood Atropine for Myopia Progression	US 63419650	26 October 2022	USA
Vyluma Inc.	Childhood Atropine for Myopia Progression	US 63419675	26 October 2022	USA
Vyluma Inc.	TOAST Abstract	US 63348256	2 June 2022	USA
Vyluma Inc.	TOAST Poster	US 63402374	30 August 2022	USA
Vyluma Inc.	Low-Dose Carbachol Ophthalmic Compositions With Cumulative Effect	PCT/IB2022/054864	25 May 2022	PCT Countries
Vyluma Inc.	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	US 11273141	18 May 2021	USA
Vyluma Inc.	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	US 17/591,944	3 February 2022	USA

Owner	Description	Patent/App. No.	File Date	Jurisdiction
Vyluma Inc	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	21809576.8	11 November 2022	Europe
Vyluma Inc	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	3,178,254	8 November 2022	Canada
Vyluma Inc	Low-Dose Ophthalmic Compositions and Methods	PCT/US21/43061	23 July 2021	PCT Countries
Vyluma Inc	Methods and Formulation for Topical Administration of Gabapentenoids	PCT/US2022/017997	25 February 2022	PCT Countries
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10226436	30 January 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10159657	10 April 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10471026	17 October 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10420735	17 October 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10646458	3 January 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10568850	3 January 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 11413259	3 April 2020	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 17861752	11 July 2022	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 17872450	25 July 2022	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	3,051,467	24 July 2019	Canada
Nevakar Injectables Inc.	Vancomycin Liposome Composition and Methods	US 17612551	18 November 2021	USA
Nevakar Injectables Inc.	Vancomycin Liposome Composition and Methods	JP 2021-570935	26 November 2021	Japan
Nevakar Injectables Inc.	Vancomycin Liposome Composition and Methods	EP20813948.5	28 October 2021	Europe
Nevakar Injectables Inc.	Formulations for Treating Pain	US 10052296	21 August 2018	USA
Nevakar Injectables Inc.	Formulations for Treating Pain	US 10,874,626	05 October 2018	USA
Nevakar Injectables Inc.	Formulations for Treating Pain	US 17/098,923	16 November 2020	USA
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	11,547,686	2 April 2020	USA
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	18/076,264	6 December 2022	USA
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	18864043.7	30 April 2020	Europe
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	3075414	9 March 2020	Canada
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	2018800783614.00	3 June 2020	China
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	2020-518795	1 April 2020	Japan
Nevakar Injectables Inc.	Fixed Dose Composition Formulations for Treating Pain	16/644,022	3 March 2020	USA

Owner	Description	Patent/App. No.	File Date	Jurisdiction
Nevakar Injectables Inc.	Fixed Dose Composition Formulations for Treating Pain	18860180.1	12 March 2020	Europe
Nevakar Injectables Inc.	Liquid Unit Dosage Forms for Treatment of Postoperative Pain	PCT/US22/16636	16 February 2022	PCT Countries
Nevakar Injectables Inc.	Injectable Pregabalin Formulations	PCT/US2022/031982	2 June 2022	PCT Countries
Nevakar Injectables Inc.	Methods For Reducing Catecholamine-Formaldehyde Adducts	18/011,664	20 December 2022	USA
Nevakar Injectables Inc.	Injectable Compositions of Vitamers of Vitamin B12 and Uses Thereof	US 63/314724	28 February 2022	USA
Nevakar Injectables Inc.	Injectable Compositions of Vitamers of Vitamin B12 and Uses Thereof	US 63/314724	28 February 2022	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10682308	11 February 2019	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10722453	31 March 2020	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10722454	31 March 2020	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10722455	31 March 2020	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 16909340	23 June 2020	USA
Nevakar Injectables Inc.	Ephedrine Compositions and Methods	US 10,869,845	22 January 2020	USA
Nevakar Injectables Inc.	Ephedrine Compositions and Methods	US 11,491,121	12 November 2020	USA
Nevakar Injectables Inc.	Ephedrine Compositions and Methods	US 17/960,343	5 October 2022	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 10,653,646	21 March 2019	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 11,071,719	12 February 2020	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 11,207,280	17 March 2020	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 11,083,698	17 March 2020	USA
Nevakar Injectables Inc.	Epinephrine Composition and Containers	US 17/526,786	15 November 2021	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Containers	3093725	21 March 2019	Canada

EXHIBIT "C"**Trademarks**

<u>Owner</u>	<u>Description</u>	<u>Serial/ Registration No.</u>	<u>File Date</u>	<u>Jurisdiction</u>
Nevakar	NEVAKAR	5,024,098	August 16, 2016	US
Nevakar	REPOSITIONING DRUGS FOR A BETTER OUTCOME	5,128,464	January 24, 2017	US
Nevakar	QUALITY WITHOUT BORDERS	5,466,189	May 8, 2018	US
Vyluma	MyMyopia.com	6,199,967	November 1, 2020	US
Nevakar	NuPharming	6,702,564	April 12, 2022	US
Vyluma	Mylumo	90,865,247	August 4, 2021	US, Peru, Hong Kong, Argentina, UK, New Zealand, WIPO # (1,681,020)
Vyluma	Eyalta	Applic. #97663849	November 4, 2022	US
Vyluma	Eyveri	Applic. #97663824	November 4, 2022	US
Vyluma	Optm	Applic. #97663182	November 4, 2022	US
Vyluma	Vyluma	6,607,569	February 18, 2021	US

EXHIBIT "D"

Mask Works

None.